Xalkori And Zelboraf: The Highs And Lows Of Commercializing Targeted Cancer Drugs
Pfizer’s lung cancer drug Xalkori and Roche’s melanoma drug Zelboraf launched last year in tandem with companion diagnostics. But a slow launch trajectory compared to other recent cancer drugs points to pitfalls for marketing a drug to just a subset of patients.
You may also be interested in...
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
Pfizer’s emphasis on oncology has yielded three new drug approvals in the last 20 months and another two promising drugs on the horizon. It is a notable achievement, but investors may be wondering when the results are going to be felt on the top line.
Pfizer Works With Roche To Increase Diagnostic Services For Xalkori Launch In China’s Self-Pay Market
Despite no reimbursement in sight, Pfizer still sees a huge potential for targeted lung cancer drug Xalkori in China. To quickly ramp up eligible patients, Pfizer is working with Roche to offer discounted diagnostic services to identify best responders.